Drug‐Drug and Drug‐Food Interactions Between Tenofovir Disoproxil Fumarate and Didanosine
- 1 December 2005
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 45 (12) , 1360-1367
- https://doi.org/10.1177/0091270005281351
Abstract
The drug‐drug and drug‐food interactions between tenofovir DF and didanosine EC were evaluated in 2 pharmacokinetic studies in healthy adult subjects. When 400 mg was dosed with tenofovir DF, mean didanosine AUC was increased by 44% to 60% following fasted or fed administration. Staggered coadministration (2 hour, fasted) of a reduced didanosine dose of 250 mg resulted in equivalent didanosine exposure, while simultaneous administration with tenofovir DF in the fasted and fed state resulted in didanosine AUCs similar to that of the reference treatment of 400 mg alone in the fasted state. These data indicate that a dose reduction of didanosine is warranted when it is used with tenofovir DF. The drug‐drug‐food interaction of didanosine may offer more flexible dosing of didanosine EC when it is used with tenofovir DF. Patients receiving tenofovir DF and didanosine together should be carefully monitored for safety and efficacy.Keywords
This publication has 18 references indexed in Scilit:
- Role of Purine Nucleoside Phosphorylase in Interactions between 2′,3′-Dideoxyinosine and Allopurinol, Ganciclovir, or TenofovirAntimicrobial Agents and Chemotherapy, 2004
- Tenofovir Disoproxil FumarateClinical Pharmacokinetics, 2004
- Effect of Food on the Oral Bioavailability of Didanosine from Encapsulated Enteric-Coated BeadsThe Journal of Clinical Pharmacology, 2002
- Lack of Effect of Simultaneously Administered Didanosine Encapsulated Enteric Bead Formulation (Videx EC) on Oral Absorption of Indinavir, Ketoconazole, or CiprofloxacinAntimicrobial Agents and Chemotherapy, 2002
- Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected AdultsAntimicrobial Agents and Chemotherapy, 2001
- DidanosineDrugs, 1996
- Analysis of Potential Risk Factors Associated with the Development of Pancreatitis in Phase I Patients with AIDS or AIDS-Related Complex Receiving DidanosineThe Journal of Infectious Diseases, 1994
- Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonatesAntimicrobial Agents and Chemotherapy, 1993
- Food-induced reduction in bioavailability of didanosineClinical Pharmacology & Therapeutics, 1991
- Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome—related complexClinical Pharmacology & Therapeutics, 1991